
|Videos|April 14, 2022
Investigational oral agent noninferior to intravenous ertapenem for complicated UTIs
Author(s)Urology Times staff
“Oral tebipenem pivoxil hydrobromide and intravenous ertapenem had a similar safety and tolerability profile,” says Angela Talley, MD.
Advertisement
In this video, Angela Talley, MD, discusses the background and notable findings of the recent New England Journal of Medicine paper, “Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,” for which she served as senior author. Talley is senior vice president of Clinical Development at Spero Therapeutics.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Practical uses of AI across the urologic care continuum
2
Study progresses of nogapendekin alfa inbakicept for BCG-naïve NMIBC
3
The UroOnc Minute: Diet and Prostate Cancer, with Stephen J. Freedland, MD
4
Walter Hsiang, MD, discusses insurance-related barriers to kidney stone care
5



















